Non-Invasive Cancer DiagnosticsMarket - Regional Analysis
On the basis of region, theglobal Non-InvasiveCancer Diagnostics Market is segmented into North America, Latin America,Europe, Asia Pacific, Middle East, and Africa. North America holds a dominantposition in the non-invasive diagnostics market, owing to increasing incidenceof cancer, increasing technological advancement, better reimbursement scenario,and governmental initiatives for screening of cancer in early stages. For instance,the American Cancer Society Guidelines for the early detection of cancer offersvarious screening plans at different ages. For example, the guidelines suggestthat women between the age of 40 and 44 must screen for breast cancer annually.Moreover market players in the APAC region are involved in partnerships andagreements to enhance the market growth in cancer diagnostics. For instance, InApril 2019, Halifax signed an exclusive distribution agreement with Genecast tomake Immunoscore assay available in China.
Non-Invasive Cancer DiagnosticsMarket – Competitive Landscape
Some of the key players operatingin the global non-invasive cancer diagnostics market include Roche Diagnostics,Hologic Inc., Qiagen, Gen-Probe Inc., Digene Corporation, Abbott Molecular,IVDiagnostics, Laboratory Corporation of America Holdings, OncoCyteCorporation, Arquer Diagnostics Ltd. and Affymetrix Inc.
Increasing product launches as apart of organic strategies to rule the market is also the key factorcontributing to the non-invasive cancer diagnostics market growth. Forinstance, in March 2019, NeoGenomics Laboratories Inc. announced the launch ofVentana PD-L1 (SP142) Assay for tumor tissue testing in patients with a triplenegative subtype of breast cancer. The test is approved by the US FDA forpatients who might respond to TECENTRIQ, an immune checkpoint inhibitor incombination with chemotherapy.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1651
Non-invasive cancer diagnosticsare procedures used for the identification of cancer without incision in thebody. Detection and treatment of cancer at early stages are important forlong-term survival. Non-invasive cancer detection method is found to be anincreasing choice of interest, owing to its painless or minimal pain method ofdiagnostic coupled with more accurate results. Molecular based diagnosticmethods are expected to increase during the forecast period due to launches ofnew biomarker based detection methods. Moreover, factors like increasingincidence of cancer, increasing cancer screening rate, government initiatives,and emerging technologies such as next generation sequencing are expected todrive the market during the forecast period.
According to Cancer Research UK,currently no diagnostic tests are 100% sensitive in general practice. This suggeststhe unmet demand for novel diagnostic assay with more efficiency. Theefficiency of molecular diagnostics for screening of blood and tissue samplefor cancer detection fuels the research and development of biomarker basedmolecular diagnostic method, which can detect abnormalities in their earlydevelopmental cycle. Moreover, according to Genome Biology article published in2017, the current research in non-invasive cancer detection are targeting twoclass of studies - the development of biomarkers for a specific cancer type andthe characterization of circulating tumor DNA (ctDNA) for general cancerdetection, without trying to predict specific cancer types. Such studies willhelp manufacturers to develop better cancer detection kits for molecular baseddiagnostics.
Non-Invasive Cancer DiagnosticsMarket Drivers
Increasing incidence of cancer isexpected to be a major factor driving growth of non-invasive cancer diagnosticsmarket. Cancer is a major factor impacting the world economy. For instance, accordingto the World Health Organization (WHO) 2018 Factsheet, Cancer is the secondleading cause of death globally, and is responsible for an estimated 9.6million deaths in 2018. Globally, about 1 in 6 deaths is occurred due tocancer.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/non-invasive-cancer-diagnostics-market-1651
Increasing rate of cancerdetection will also boost the non-invasive cancer diagnostics market growth.According to the U.S. Breast Cancer Surveillance Consortium (BCSC) researchers,the rate of cancer detection increased to 34.7 per 1,000 individuals in 2013,as compared to 25.3 per 1,000 individuals in 2005. Furthermore, governmentaland non-governmental organizations are engaged in raising awareness for breastand cervical cancer as well as conducts screening programme. The NationalInstitute for Health and Care Excellence (NICE) is involved in improvingdiagnosis rate by revising draft guideline for early cancer detection.Moreover, increasing cancer studies for cancer drug development will boost thenon-invasive cancer diagnostics market growth. In 2016, NCI's Center to ReduceCancer Health Disparities launched the National ‘Screen to Save’ ColorectalCancer Outreach and Screening Initiative. The initiative was aimed atincreasing colorectal cancer screening rate.
Further, in 2016, ExosomeDiagnostics, Inc. launched ExoDx Prostate (IntelliScore) test. The test usesgenetic information from urine sample to evaluate patient risk for high gradeprostate cancer.
In 2016, Laboratory Corporationof America Holdings, launched Epi proColon, the first FDA-approved DNA basedblood test for colorectal cancer screening with FDA approval.
The inorganic strategies bymarket players are continuously boosting the non-invasive cancer diagnosticsmarket. For instance, For instance, in November 2018, Belgian moleculardiagnostics company, Biocartis Group entered into an agreement with AstraZenecafor development of lung cancer molecular diagnostic biomarker.
In 2017, Lonza, abiopharmaceutical development and manufacturing company, acquired HanaBioMaedLife Sciences OU, a company dedicated to research and development,manufacturing and distribution of products for the exosome genome market.Through this acquisition, company will invest to develop exosome-basedearly-stage cancer screening and molecular diagnostic tests. In same year, COREDiagnostics partnered with CellMax Life to introduce CellMax’s genetic cancerrisk test and ctDNA-based liquid biopsy throughout India.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1651
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
Coherent MarketInsights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
